* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 count...
Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023...
Spurring a Seamless R&D, Manufacturing, and Commercialisation Positive Cycle SHANGHAI, July 3, 2023...
SHANGHAI, April 17, 2023 /PRNewswire/ -- As a global innovative biopharmaceutical company, Henlius ...
SHANGHAI, April 1, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 annual results. In 202...
* HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell...
* The first Chinese biosimilar approved in both China and the EU, and potentially to be approved ...
* World's first anti-PD-1 mAb for the first-line treatment of SCLC * Making a new record with th...
SHANGHAI, Nov. 30, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...
SHANGHAI, Nov. 1, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that its...
* ASTRUM-005 is the first study to demonstrate that PD-1 inhibitors plus chemotherapy can improve...
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its 2022 interim results. As a ...
SHANGHAI, July 26, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...
* Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialida...
SHANGHAI, June 6, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that an ...
SHANGHAI, April 11, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that th...
SHANGHAI, April 7, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...
SHANGHAI, March 25, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that it...
SHANGHAI, March 17, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the yea...
SHANGHAI, March 16, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the yea...